Leap Therapeutics, Inc. (LPTX)
NASDAQ: LPTX · Real-Time Price · USD
0.4010
-0.0110 (-2.67%)
At close: May 16, 2025, 4:00 PM
0.3900
-0.0110 (-2.74%)
After-hours: May 16, 2025, 6:31 PM EDT
Leap Therapeutics Employees
Leap Therapeutics had 52 employees as of December 31, 2024. The number of employees decreased by 2 or -3.70% compared to the previous year.
Employees
52
Change (1Y)
-2
Growth (1Y)
-3.70%
Revenue / Employee
n/a
Profits / Employee
-$1,339,192
Market Cap
16.54M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
LPTX News
- 5 days ago - Leap Therapeutics Reports First Quarter 2025 Financial Results - PRNewsWire
- 22 days ago - Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting - PRNewsWire
- 4 weeks ago - Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer - PRNewsWire
- 6 weeks ago - Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript - Seeking Alpha
- 7 weeks ago - Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer - Benzinga
- 7 weeks ago - Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 7 weeks ago - Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study - PRNewsWire
- 3 months ago - Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study - PRNewsWire